Gut-Brain Axis — 2026-05-21

🔬 Latest Research Highlights

Predicting Alzheimer’s Risk via AI, Diet, and Gut Microbiome

• Research Team: Reported by Athens Times (2026-05-21, 18 hours ago)
• Key Finding: A new approach has emerged that uses AI to predict Alzheimer's risk by analyzing dietary patterns and gut health status. Unlike traditional invasive tests, this method utilizes simple questionnaires to improve prediction. The study reaffirmed that fiber intake and microbiome diversity are closely linked to the maintenance of cognitive function.
• Significance: By enabling early Alzheimer's screening based solely on diet and gut health data, this tool could be widely applied in healthcare settings with limited access to blood tests or brain imaging.

Coffee Reshapes Both the Gut and Brain

• Research Team: Reported by ScienceDaily (2026-05-17, 4 days ago)
• Key Finding: Both caffeinated and decaf coffee appear to shift gut bacteria composition in ways associated with improved mood and stress reduction. Decaf coffee, in particular, showed improvements in learning and memory, while caffeinated coffee was linked to enhanced focus and reduced anxiety.
• Significance: This suggests that the impact of coffee on brain function isn't just about caffeine but also occurs through pathways involving gut microbial changes, which may spur further research into coffee as a dietary strategy for mental health.

2 sources

sciencedaily.com

sciencedaily.com

sciencedaily.com

sciencedaily.com

The Brain-Gut-Skin Axis: A New Paradigm for Chronic Skin Diseases

• Research Team: Reported by AJMC (2026-05-20, 1 day ago)
• Key Finding: Chronic skin diseases like atopic dermatitis and psoriasis are increasingly understood not just as localized skin issues, but as systemic conditions connected by the brain-gut-skin axis. A mechanism has been identified where gut microbiome imbalance affects both the skin and brain simultaneously via inflammatory signals.
• Significance: This provides clinical evidence that an integrative approach, combining dermatological treatment with gut microbiome regulation, could enhance therapeutic efficacy for chronic skin conditions.

💊 Clinical Trials & Drug Trends

• Microbiome Drugs, From Wellness to Clinic: Results from trials show that gut bacteria can help overcome immunotherapy resistance in some melanoma patients. According to a report by Longevity Technology (2026-05-19, 2 days ago), microbiome-based drugs are moving beyond supplements and health foods to become serious candidates as adjuncts to cancer immunotherapy. Notably, a cluster of about 50 bacterial strains extracted from the feces of specific patients induced immunotherapy responses in patients with advanced colorectal cancer.

• Psychobiotics Human Clinical Trial Review: Frontiers in Microbiology (March 2026) published a comprehensive analysis of human clinical trials evaluating mental health improvements via the gut-brain axis. Lactobacillus and Bifidobacterium probiotics showed significant effects in alleviating anxiety and depression, though standardizing strain selection, dosage, and duration remains a challenge.

🏢 Industry & Business

• Kanvas Biosciences Secures $48 Million in Series A: Kanvas Biosciences, a developer of spatial biology-based microbiome therapeutics, has completed a $48 million Series A funding round (May 2026). They focus on developing gut microbiome therapeutics for cancer patients, with a proprietary cluster of over 50 bacterial strains identified from the feces of healthy cancer survivors.

• Nestlé Joins Microbiome Therapeutics Innovation Group (MTIG): Global food giant Nestlé has joined MTIG (April 2026), an independent coalition aimed at advancing FDA-approved microbiome therapies. The involvement of a major food and nutrition company in the microbiome ecosystem is accelerating the convergence of industry boundaries.

🧠 Deep Dive: How Coffee Simultaneously Changes the Gut and Brain

While it is well known that coffee affects mood and cognitive function, recent findings indicate that a significant portion of this pathway occurs through the gut-brain axis.

Beyond its known caffeine effect of blocking adenosine receptors, coffee also alters the composition of the gut microbiota. Studies show that after consuming coffee (both caffeinated and decaf), beneficial bacteria such as Bifidobacterium and Lactobacillus increase. These bacteria produce short-chain fatty acids (SCFAs) and serotonin precursors, which transmit signals to the brain via the vagus nerve, leading to mood stabilization and reduced anxiety.

Interestingly, decaf coffee also improved brain functions related to learning and memory. This means that non-caffeine components, such as polyphenols in coffee, can exert neuroprotective effects through gut microbes. The remaining question is precisely identifying which coffee components act on which neural circuits via specific bacterial strains.

📋 Action Guide

1. Drink Coffee Consistently, but in Moderation: Both caffeinated and decaf coffee increase beneficial gut bacteria. One to two cups a day can contribute to gut-brain axis health. However, consider personal sensitivity as excessive caffeine can worsen anxiety.

2. Boost Alzheimer's Prevention via Fiber Intake: AI-based research confirms that a fiber-rich diet and microbiome diversity are key protective factors. Including whole grains, legumes, and vegetables in every meal promotes SCFA production, which helps suppress neuroinflammation in the brain.

3. Check Your Gut Health if You Have Chronic Skin Issues: According to the brain-gut-skin axis research, skin inflammation like atopic dermatitis or psoriasis can be linked to gut microbiome imbalances. Regularly consuming probiotic foods (yogurt, kimchi, doenjang) to improve the gut environment may help alleviate skin symptoms.

4. Focus on the Microbiome if Undergoing Immunotherapy: The latest clinical research shows that gut bacterial composition can directly affect immunotherapy response rates. Avoid unnecessary antibiotic use and maintain a plant-based diet to protect microbiome diversity. Consider discussing microbiome management with your physician before treatment.

👀 Key Takeaways

• Standardization of Psychobiotics Clinical Trials: Results remain difficult to compare because strain selection, dosage, and duration vary across studies. Multi-center collaborative standardization trials are expected to be announced in the second half of 2026.

• Expansion of Microbiome × Immunotherapy Trials: Startups like Kanvas Biosciences are preparing Phase 2 trials for microbiome therapeutics in combination with immune checkpoint inhibitors. Interim data is expected in the second half of 2026, which could lead to fast-track FDA consideration.

• Competition in Brain-Gut-Skin Axis Therapeutics: Multiple clinical trials are being designed in this intersection of dermatology, neurology, and gastroenterology. Early results from trials using probiotic adjunct therapy for atopic dermatitis patients are expected later this year.